Related Experiment Videos
Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms
A R Tabrizi1, S D McGrath, M A Blinder
1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
American Journal of Hematology
|May 9, 2001
Summary
Genetic variations in cytochrome P450 (CYP) enzymes significantly impact warfarin metabolism. Two siblings with extreme warfarin sensitivity shared a unique CYP genotype, highlighting the role of genetics in drug response and the potential of genetic testing for personalized warfarin dosing.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Cytochrome P450 Enzymes
Background:
- Warfarin, a widely used anticoagulant, exhibits significant inter-individual variability in dose response.
- Warfarin metabolism is primarily influenced by cytochrome P450 (CYP) enzymes, specifically CYP2C9 and CYP1A2.
- Understanding genetic factors affecting CYP activity is crucial for optimizing warfarin therapy.
Observation:
- Two siblings presented with an unusually high sensitivity to warfarin.
- These individuals possessed a rare and specific cytochrome P450 (CYP) genotype.
- Their clinical presentation suggested a significant genetic influence on warfarin pharmacokinetics.
Findings:
- The siblings' extreme warfarin sensitivity was directly linked to their uncommon CYP genotype.
- This case demonstrates the critical role of genetic makeup in determining an individual's response to warfarin.
- The identified CYP genotype likely results in altered warfarin metabolism.
Implications:
- Genetic testing for CYP genotypes may predict warfarin sensitivity or resistance.
- Personalized warfarin dosing guided by pharmacogenetics can improve treatment efficacy and safety.
- This research underscores the potential of genetic screening to guide anticoagulant prescribing practices.